Jonathan Hsu
CTO Gensaic
Jonathan Hsu is the Chief Technology Officer and Co-Founder of Gensaic, a biotech company developing next-generation gene delivery platforms. A seasoned expert in computational biology, his work focuses on leveraging machine learning for tissue-selective delivery and computational protein design. Prior to co-founding Gensaic, Jonathan was a researcher at Harvard University, pioneering applications of machine learning in gene editing. His extensive research background includes roles at the Salk Institute for Biological Studies and Illumina, where he honed his expertise in genomics and epigenetics. He has also served as a Scientific Consultant for SoftBank Investment Advisers, guiding investments in the life sciences sector.
Seminars
The rapid evolution of in silico tools is revolutionizing RNAi therapeutic development, from target discovery to regulatory approval. Attendees will learn how to leverage these tools to expand RNAi applications beyond
current frontiers, optimize drug stability, and navigate regulatory hurdles. A must for teams aiming to harness data-driven approaches for faster, smarter RNAi therapeutic design.
Discussion highlights include:
- Deploying AI-powered genomic and transcriptomic analysis to uncover high-confidence RNAi targets, and directed evolution-based discovery of novel protein-to-protein interactions governing tissue-selective, extrahepatic delivery of siRNA.
- Applying machine learning to predict off-target effects and potency, streamlining lead candidate selection, and reducing late-stage attrition in preclinical development
- Utilizing computational modelling to connect sequence and structure with functional data layers, such as predicting ligands for orphan receptors, binding affinity, internalization dynamics and stability, to accelerate discovery and translation of early leads.
